# Hyperlipidemia; Hypercholesterolemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hyperlipidemia-hypercholesterolemia

> 2 upcoming FDA catalysts in hyperlipidemia; Hypercholesterolemia: Lipfendra (enlicitide decanoate, MRK) on Nov 2027 to Feb 2028 (topline data readout); Lipfendra (enlicitide decanoate, MRK) on November 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2027 to Feb 2028 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hyperlipidemia; Hypercholesterolemia | scheduled | "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821944)) |
| November 2027 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hyperlipidemia; Hypercholesterolemia | scheduled | "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821944)) |

## Drugs

- [Lipfendra (enlicitide decanoate)](https://sec-api.dev/pdufa/enlicitide-decanoate) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hyperlipidemia-hypercholesterolemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hyperlipidemia; Hypercholesterolemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hyperlipidemia-hypercholesterolemia

```bibtex
@misc{secapidev_indications_hyperlipidemia_hypercholesterolemia_20261116,
  title        = {Hyperlipidemia; Hypercholesterolemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hyperlipidemia-hypercholesterolemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hyperlipidemia_hypercholesterolemia_20261116","title":"Hyperlipidemia; Hypercholesterolemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hyperlipidemia-hypercholesterolemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
